Skip to main content

Bristol-Myers Squibb vs Pfizer: Revenue, Profit and Business Model

Bristol-Myers Squibb had $48.2B of annual revenue in FY2025 and $7.1B of net income. Pfizer had $62.6B of annual revenue in FY2025 and $7.8B of net income.

Latest financial snapshot

Bristol-Myers Squibb

Latest annual revenue
$48.2B (FY2025)
Net income
$7.1B
Net margin
14.6%
Revenue growth
+10.6% a year, FY2016–FY2025

Pfizer

Latest annual revenue
$62.6B (FY2025)
Net income
$7.8B
Net margin
12.4%
Revenue growth
+1.9% a year, FY2016–FY2025

Financial summary

Bristol-Myers Squibb

Revenue grew from $19.4 billion in 2016 to $42.5 billion in 2020 as Celgene's sales were added, and has stayed between $45.0 billion and $48.3 billion since 2021. Net earnings are far less stable because BMS expenses acquired in-process R&D: the $11.4 billion MyoKardia charge produced a $9.0 billion net loss in 2020, and the Karuna charge produced an $8.9 billion loss in 2024. Cash generation is steadier, with free cash flow of about $12.8 billion in 2025. That cash funds a dividend raised for a 17th straight year in February 2026, to $0.63 a quarter, and debt reduction, from $51.2 billion at the end of 2024 to $47.2 billion a year later. On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion, from $46.0 to $47.5 billion, after second-quarter revenue rose 6 percent to $12.97 billion. Bristol Myers Squibb is a dominant force in global biopharmaceuticals, sustaining a massive market valuation that regularly exceeds $100 billion.

Pfizer

Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%. Pfizer ranks among the largest pharmaceutical companies in the world, carrying a market valuation typically exceeding $150 billion.

Revenue and profit by year

Bristol-Myers Squibb

Bristol-Myers Squibb revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$48.2B$7.1B14.6%-0.2%Source
FY2024$48.3B-$8.9B-18.5%+7.3%Source
FY2023$45B$8B17.8%-2.5%Source
FY2022$46.2B$6.3B13.7%-0.5%Source
FY2021$46.4B$7B15.1%+9.1%Source
FY2020$42.5B-$9B-21.2%+62.6%Source
FY2019$26.1B$3.4B13.2%+15.9%Source
FY2018$22.6B$4.9B21.8%+8.6%Source
FY2017$20.8B$1B4.8%+6.9%Source
FY2016$19.4B$4.5B22.9%—Source
Full Bristol-Myers Squibb financials

Pfizer

Pfizer revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$62.6B$7.8B12.4%-1.6%Source
FY2024$63.6B$8B12.6%+6.8%Source
FY2023$59.6B$2.1B3.6%-41.1%Source
FY2022$101.2B$31.4B31.0%+24.5%Source
FY2021$81.3B$22B27.0%+95.2%Source
FY2020$41.7B$9.2B22.0%+1.8%Source
FY2019$40.9B$16B39.2%+0.2%Source
FY2018$40.8B$11.2B27.3%-22.3%Source
FY2017$52.5B$21.3B40.6%-0.5%Source
FY2016$52.8B$7.2B13.7%—Source
Full Pfizer financials

Where the revenue comes from

Bristol-Myers Squibb

  • Growth Portfolio~55%

    $26.4 billion in 2025, up 17%: Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Sotyktu, Cobenfy, Krazati and other newer brands. It grew another 15% to $7.56 billion in the second quarter of 2026.

  • Legacy Portfolio~45%

    $21.8 billion in 2025: Eliquis ($14.4 billion), Revlimid ($3.0 billion), Pomalyst/Imnovid ($2.7 billion), Sprycel, Abraxane and other mature brands facing generic competition. Legacy revenue fell 4% in the second quarter of 2026.

Pfizer

  • Patented medicines

    Core revenue

    Prescription drugs protected by exclusivity and clinical differentiation.

  • Vaccines

    Major revenue contributor

    Adult, pediatric, pneumococcal, RSV, and COVID-related vaccines.

  • Oncology

    Strategic growth driver

    Cancer medicines, antibody-drug conjugates, and Seagen-related assets.

  • Hospital and anti-infective products

    Meaningful contributor

    Sterile injectables, anti-infectives, and hospital therapies.

  • Collaborations and alliances

    Supplemental

    Co-promoted products and partnered scientific platforms.

Business model and strategy

Bristol-Myers Squibb

How it makes money

Bristol Myers Squibb Company (BMS) discovers, develops, and delivers innovative medicines across four core therapeutic areas: Oncology, Hematology, Cardiovascular, and Immunology. Commercial revenues are categorized into a Legacy Blockbuster Portfolio and a high-growth New Product Portfolio.

Growth strategy

BMS is pursuing growth on three fronts. First, scaling the Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy and others), which rose 17 percent to $26.4 billion in 2025 and 15 percent to $7.56 billion in the second quarter of 2026.

Competitive advantage

Bristol Myers Squibb's competitive moat is founded on deep clinical leadership in immuno-oncology, pioneering CAR-T cell therapy manufacturing, and a first-in-class neuroscience mechanism for psychiatric disorders. By discovering and developing Opdivo and Yervoy, BMS pioneered dual checkpoint inhibition in oncology.

Bristol-Myers Squibb business model in full

Pfizer

How it makes money

Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies. Pfizer's commercial model operates across several primary therapeutic areas: Oncology, Vaccines, Internal Medicine, Hospital and Anti-Infectives, and Inflammation & Immunology.

Growth strategy

Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total).

Competitive advantage

Pfizer's economic moat is rooted in its immense global clinical trial scale, unmatched commercial distribution infrastructure, and specialized aseptic vaccine manufacturing capabilities.

Pfizer business model in full

Questions about Bristol-Myers Squibb vs Pfizer

Which company has higher revenue — Bristol-Myers Squibb Company or Pfizer Inc.?

Bristol-Myers Squibb Company had $48.2B (FY2025), while Pfizer Inc. had $62.6B (FY2025). By latest annual revenue, Pfizer Inc. is the larger business, with Bristol-Myers Squibb Company showing a smaller revenue base.

What is the market cap of Bristol-Myers Squibb Company vs Pfizer Inc.?

Bristol-Myers Squibb Company's market capitalisation stands at $127.5B, while Pfizer Inc.'s is $160.3B. Pfizer Inc. carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Bristol-Myers Squibb Company.

How does revenue per employee compare for Bristol-Myers Squibb Company and Pfizer Inc.?

Bristol-Myers Squibb Company has $1.48M / employee in revenue per employee, while Pfizer Inc. has $834k / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do Bristol-Myers Squibb Company and Pfizer Inc. make money?

Bristol-Myers Squibb Company and Pfizer Inc. generate revenue in fundamentally different ways. Bristol-Myers Squibb Company: Bristol Myers Squibb Company (BMS) discovers, develops, and delivers innovative medicines across four core therapeutic areas: Oncology, Hematology, Cardiovascular, and Immunology. Pfizer Inc.: Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies.

Which company is valued higher relative to revenue — Bristol-Myers Squibb Company or Pfizer Inc.?

On a price-to-sales (P/S) basis, Bristol-Myers Squibb Company trades at 2.6x P/S and Pfizer Inc. at 2.6x P/S. Bristol-Myers Squibb Company commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Pfizer Inc.. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.

Is Bristol-Myers Squibb Company bigger than Pfizer Inc.?

By last reported revenue, Pfizer Inc. ($62.6B (FY2025)) is the larger company compared to Bristol-Myers Squibb Company ($48.2B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Pfizer overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.